Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.

A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97

Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res (2012) 1.40

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24

Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics (2014) 1.16

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res (2013) 1.00

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00

The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem (2013) 0.95

Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94

Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. Biomed Res Int (2013) 0.93

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest (2012) 0.92

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med (2015) 0.92

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2014) 0.90

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer (2014) 0.90

Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr Med Chem (2012) 0.86

Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation. Oncotarget (2016) 0.85

Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation. Endocrinology (2012) 0.84

A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling. Mol Cancer (2014) 0.80

Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget (2015) 0.79

SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression. Oncotarget (2015) 0.79

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget (2015) 0.78

Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Sci Rep (2016) 0.76

An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells. PLoS One (2015) 0.76

The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth. J Biol Chem (2016) 0.75

Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells. Int J Mol Sci (2016) 0.75

Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites. Hum Mutat (2015) 0.75

Re: overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. J Urol (2012) 0.75

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. EBioMedicine (2017) 0.75

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37

Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A (1997) 3.22

Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07

Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90

Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74

Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res (1996) 1.98

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98

Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97

Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94

Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem (1997) 1.92

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem (2000) 1.91

Ornithine decarboxylase in mouse kidney. Purification, characterization, and radioimmunological determination of the enzyme protein. J Biol Chem (1983) 1.88

The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol (1998) 1.86

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer (1991) 1.85

Androgen induction of ornithine decarboxylase mRNA in mouse kidney as studied by complementary DNA. Proc Natl Acad Sci U S A (1984) 1.81

Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol (2001) 1.71

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71

The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.70

Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem (1999) 1.65

Placental alkaline phosphatase as a tumor marker for seminoma. Cancer Res (1982) 1.63

Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol (1998) 1.60

Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem (1996) 1.60

Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59

Novel assay for determination of androgen bioactivity in human serum. J Clin Endocrinol Metab (2001) 1.57

ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol (2000) 1.55

CHEK2 variants associate with hereditary prostate cancer. Br J Cancer (2003) 1.54

Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res (2000) 1.52

A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins. J Biol Chem (1999) 1.51

Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50

Osteoprotegerin and rank ligand expression in prostate cancer. Urology (2001) 1.50

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47

CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci U S A (1998) 1.47

Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42

Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem (2004) 1.42

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene (2012) 1.40

Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry (1994) 1.39

Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology (1994) 1.37

Complete amino acid sequence of human placental protein 14: a progesterone-regulated uterine protein homologous to beta-lactoglobulins. Proc Natl Acad Sci U S A (1988) 1.36

The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci (2000) 1.34

Complete amino acid sequence of human ornithine decarboxylase deduced from complementary DNA. DNA (1987) 1.32

Human ornithine decarboxylase-encoding loci: nucleotide sequence of the expressed gene and characterization of a pseudogene. Gene (1990) 1.30

Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev (1999) 1.30

Primary structure of human insulin-like growth factor-binding protein/placental protein 12 and tissue-specific expression of its mRNA. FEBS Lett (1988) 1.29

Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol (1993) 1.26

Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol (1994) 1.26

Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol (2001) 1.25

Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res (1997) 1.23

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23

Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis (2003) 1.22

Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res (2006) 1.20

Coregulator small nuclear RING finger protein (SNURF) enhances Sp1- and steroid receptor-mediated transcription by different mechanisms. J Biol Chem (2000) 1.20

A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia. Proc Natl Acad Sci U S A (1994) 1.20

Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene (2006) 1.19

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl (1996) 1.18

Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res (2003) 1.14

Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene (2008) 1.13

The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. Oncogene (2006) 1.13

Difluoromethylornithine-induced amplification of ornithine decarboxylase genes in Ehrlich ascites carcinoma cells. Biochem Biophys Res Commun (1985) 1.13

Two ornithine decarboxylase mRNA species in mouse kidney arise from size heterogeneity at their 3' termini. Proc Natl Acad Sci U S A (1986) 1.13

Activation of androgen receptor function by a novel nuclear protein kinase. Mol Biol Cell (1998) 1.13

Transcriptional coregulator SNURF (RNF4) possesses ubiquitin E3 ligase activity. FEBS Lett (2004) 1.13

Ornithine decarboxylase mRNA in mouse kidney: a low abundancy gene product regulated by androgens with rapid kinetics. Ann N Y Acad Sci (1984) 1.12

A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer (1979) 1.12

Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol (1995) 1.12

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12

Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J Biol Chem (1997) 1.12

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol (1987) 1.11

Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res (1995) 1.11

Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate (1997) 1.10

A review on Anopheles culicifacies: from bionomics to control with special reference to Indian subcontinent. Acta Trop (2008) 1.10

Structure and regulation of mammalian S-adenosylmethionine decarboxylase. J Biol Chem (1988) 1.10

Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet (2001) 1.10

Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10

A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU Int (2004) 1.09

Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res (1988) 1.08

Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol (1993) 1.08

Nanosilica-from medicine to pest control. Parasitol Res (2008) 1.08

Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim (2001) 1.07

Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06

Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet (1998) 1.05

Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Mol Endocrinol (1993) 1.05

Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. Nucl Med Biol (1993) 1.05

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology (1999) 1.04

Mutant strain of Chinese hamster ovary cells with no detectable ornithine decarboxylase activity. Mol Cell Biol (1985) 1.04

Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res (2001) 1.03

Analysis of androgen receptor-DNA interactions with receptor proteins produced in insect cells. J Biol Chem (1994) 1.03

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer (1996) 1.02